Research programme: small molecule therapeutics - Infinity/Johnson & Johnson

Drug Profile

Research programme: small molecule therapeutics - Infinity/Johnson & Johnson

Latest Information Update: 16 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Infinity Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 14 Mar 2007 Infinity Pharmaceuticals has recognised $US1 million revenue from delivery of compounds to Johnson & Johnson under this agreement
  • 31 Dec 2005 Infinity has amended the agreement to allow for a reduction in the number of compounds to be delivered to Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top